Metastatic Melanoma: A Regional Review and Future Directions

Evaluation of combination treatment with a BRAF inhibitor (BMS-908662) and CTLA-4 monoclonal antibody in preclinical models.

(2017) M. Jure-Kunkel et al.   JOURNAL OF CLINICAL ONCOLOGY

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

(2017) A. Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

(2011) V Chiarion-Sileni et al.   BRITISH JOURNAL OF CANCER

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer

(2011) Grazia Graziani et al.   PHARMACOLOGICAL RESEARCH

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE